As of Nov 19, 2026, 1 of 1 active firms rate SPRO a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
SPRO EPS & revenue forecast
EPS · NEXT QUARTER
$-0.23
Range $-0.23 – $-0.23 · 1 analysts
Next period, 1 analysts expect Spero Therapeutics Inc to earn $-0.23 a share (range $-0.23 – $-0.23), versus — a year earlier. Full-year consensus is $-1.28, growing to $-0.98 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $300.0K, rising to $0 next year.
Top analysts covering Spero Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SPRO.
#1
Raghuram Selvaraju
HC Wainwright & Co. · Rank #423
Buy
$6.00+588.9% to target
Overall win rate
36%
+ Follow
#2
GC
Gavin Clark-Gartner
Evercore ISI Group
Neutral
$4.00+359.2% to target
Coverage
—
+ Follow
#3
Ritu Baral
TD Cowen
Neutral
No targeton SPRO
Coverage
—
+ Follow
SPRO stock forecast FAQ
What is SPRO's average 12-month price target?+
The 1 active firms with a live target average $6.00 for Spero Therapeutics Inc over the next 12 months, ranging from a $6.00 high to a $6.00 low, as of Nov 19, 2026.
Is SPRO stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 1 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
How many active Wall Street firms cover SPRO?+
1 active firms have a recognized rating on Spero Therapeutics Inc as of Nov 19, 2026, and 1 active firms carry a live 12-month price target.
Who is the most accurate analyst covering SPRO?+
Among analysts who currently cover SPRO, Raghuram Selvaraju of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #423). Their current call is Buy with a $6.00 target.
What is Spero Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.23 per share (range $-0.23 – $-0.23) across 1 analysts. Full-year EPS is projected at $-1.28, rising to $-0.98 the following year.
How much revenue is Spero Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $300.0K, growing to $0 next year.
Have analysts been upgrading or downgrading SPRO lately?+
As of Nov 19, 2026, 1 of 1 active firms rate SPRO a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SPRO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.